Research programme: skin disorder therapies - Antares/Dr Reddy's
Latest Information Update: 06 Jul 2010
At a glance
- Originator Antares Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 03 Sep 2008 Preclinical trials in Skin disorders in USA (Topical)